Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE

Key Points

• Rafferty Asset Management increased its stake in Apogee Therapeutics by 55.9%, buying 23,585 shares to hold 65,796 shares worth about $2.61 million (≈0.14% of the company) at quarter-end.
• Significant insider selling occurred this quarter: Fairmount Funds sold 1,750,000 shares for roughly $133.5 million (an 85.42% reduction) and insiders sold a total of 1,834,200 shares (~$139.7 million), though insiders still own 42.77% of the stock.
• Analysts show a consensus rating of “Moderate Buy” with a $104.92 target; the stock was trading near $72.31 (50‑day $72.61, 200‑day $60.34), market cap ≈$5.02B, and a negative P/E reflecting current losses.

Rafferty Asset Management LLC boosted its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 55.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,796 shares of the company's stock after purchasing an additional 23,585 shares during the quarter. Rafferty Asset Management LLC owned about 0.14% of Apogee Therapeutics worth $2,614,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in APGE. ANTIPODES PARTNERS Ltd grew its holdings in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock valued at $33,000 after buying an additional 246 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Apogee Therapeutics by 99.2% during the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock worth $33,000 after acquiring an additional 383 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock valued at $921,000 after acquiring an additional 694 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Apogee Therapeutics by 34.7% during the second quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company's stock valued at $158,000 after acquiring an additional 941 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in Apogee Therapeutics by 13.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company's stock valued at $369,000 after acquiring an additional 1,000 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. BTIG Research set a $137.00 price objective on shares of Apogee Therapeutics in a report on Tuesday, January 6th. Jefferies Financial Group reissued a "buy" rating and set a $95.00 price target on shares of Apogee Therapeutics in a research note on Monday, February 2nd. Royal Bank Of Canada cut their price target on Apogee Therapeutics from $83.00 to $82.00 and set a "sector perform" rating for the company in a report on Monday. UBS Group raised Apogee Therapeutics to a "strong-buy" rating in a report on Wednesday, January 7th. Finally, Wall Street Zen downgraded Apogee Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, December 6th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.92.

Apogee Therapeutics Trading Up 5.6%

Shares of NASDAQ APGE opened at $72.31 on Thursday. The company has a 50 day simple moving average of $72.61 and a two-hundred day simple moving average of $60.34. The stock has a market cap of $5.02 billion, a price-to-earnings ratio of -17.14 and a beta of 1.39. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $84.56.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.02. Analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Insider Buying and Selling at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 18,700 shares of the business's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00. Following the completion of the transaction, the insider owned 212,523 shares of the company's stock, valued at $16,542,790.32. The trade was a 8.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the completion of the sale, the director owned 298,647 shares in the company, valued at $22,786,766.10. The trade was a 85.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,834,200 shares of company stock worth $139,739,253. Insiders own 42.77% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.